Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HepatiCan
- Development stage
- Preclinical
- Lead developer
- University College London
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
HepatiCan (previously known as UCLBAL) is a bioartificial liver (BAL) support system developed by University College London and its spinout company, Hepatican. It is designed as a combined Advanced Therapy Medicinal Product (ATMP) and medical device to provide temporary liver function for patients suffering from acute or decompensated liver failure, serving as a bridge to transplantation or allowing the patient's own liver time to regenerate. The system utilizes a single-use, cryopreservable biocartridge containing approximately 70 billion human liver cells (specifically multicellular spheroids of a GMP-rederived HepG2 cell line) encapsulated in alginate microbeads. During treatment in an intensive care setting, the patient's blood is processed via an apheresis machine to separate plasma, which is then circulated through the fluidised bed bioreactor of the HepatiCan device to perform essential metabolic, synthetic, and detoxifying functions before being returned to the patient.
- Brand names
- HepatiCan
- Other names
- UCL Bioartificial LiverUCL Bioartificial Liver Machine
Beyond the preview
Go deeper on HepatiCan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepatiCan.